Premium
Differential effects of probucol on two distinct experimental rat nephrosis models
Author(s) -
Nakahama H,
Obata K,
Sugita M
Publication year - 2000
Publication title -
nephrology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 61
eISSN - 1440-1797
pISSN - 1320-5358
DOI - 10.1046/j.1440-1797.2000.00012.x
Subject(s) - probucol , nephrosis , medicine , endocrinology , intraperitoneal injection , glomerulonephritis , nephrotic syndrome , kidney , cholesterol
Summary We compared an antiproteinuric effect of a lipid‐lowering agent probucol on two distinct types of experimental nephrosis in rats, i.e. mercuric–chloride (HgCl 2 )‐induced autoimmune glomerulonephritis in Brown Norway (BN) rats and puromycin aminonucleoside (PA)‐nephrosis in Wistar rats. The rats were fed either standard rat chow or chow containing 5% probucol. BN rats were treated with HgCl 2 according to a standard protocol (HgCl 2 1 mg/kg subcutaneously three times/week). Probucol treatment did not ameliorate proteinuria, renal histology or a strong linear staining for IgG and an intercellular adhesion molecule, ICAM‐1, in glomeruli. Wistar rats were made nephrotic with an intraperitoneal injection of PA (100 mg/kg). In this model, in contrast to the BN rat model, no glomerular deposition of IgG or ICAM‐1 was observed. Probucol treatment ameliorated proteinuria significantly. These findings suggest that the response to probucol differs in different experimental nephrosis models. As probucol only affects PA‐nephrosis, in which ICAM‐1 expression is negative, the ICAM‐1 attenuation is not likely to be involved in the antiproteinuric effect of probucol.